Other Non-Marketable Equity Securities |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Other Non-Marketable Equity Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
| OTHER NON-MARKETABLE EQUITY SECURITIES | NOTE 10 – OTHER NON-MARKETABLE EQUITY SECURITIES:
In May 2026, the Company entered into a Simple Agreement for Future Equity (the “SAFE”) with Hopec Pharma Ltd. (“Hopec”), pursuant to which the Company agreed to invest up to $1,000 in Hopec. The Company invested $500 upon entering into the SAFE and, at the Company’s discretion, may invest an additional $500 following receipt of written notice of the successful results from the Week 14 cystoscopy assessment of the third patient in the first cohort of Hopec’s clinical study. |
||||||||||||||||||||||||||||||||||||||||||||||||